Search by drug, manufacturer, or indication

Displaying 731 - 740 of 1165

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Metastatic Urothelial Carcinoma

Last updated April 15, 2020

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Classic Hodgkin's Lymphoma

Last updated April 15, 2020

Verzenio (abemaciclib)

Status:

Concluded without agreement

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Advanced or Metastatic Breast Cancer

Last updated November 14, 2022

Sublocade (buprenorphine)

Status:

Concluded with an LOI

Manufacturer:

Indivior UK Limited

Indication:

Opioid Use Disorder

Last updated April 8, 2020

Ibrance/fulvestrant (palbociclib/fulvestrant)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Advanced or Metastatic Breast Cancer

Last updated April 8, 2020

Triamcinolone Hexacetonide (triamcinolone hexacetonide)

Status:

Concluded with an LOI

Manufacturer:

Medexus Pharmaceuticals, Inc.

Indication:

Rheumatoid Arthritis

Last updated March 31, 2020

Segluromet (ertugliflozin/metformin hydrochloride)

Status:

Concluded without agreement

Manufacturer:

Merck Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated March 31, 2020

Steglatro (ertugliflozin)

Status:

Concluded without agreement

Manufacturer:

Merck Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated March 31, 2020

Orfadin Oral Suspension (nitisinone)

Status:

Concluded without agreement

Manufacturer:

Sobi Canada Inc.

Indication:

Hereditary Tyrosinemia Type 1

Last updated March 30, 2020

Xalkori (crizotinib)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

ROS1-positive advanced Non-Small Cell Lung Cancer

Last updated March 20, 2020